natgillin/translations-raw huggingface dataset:
The percentage of patients achieving ACR 20 response by visit is shown in Figure 2. 
Na sliki 2 so po posameznih obiskih prikazani odstotki bolnikov, ki so dosegli odziv ACR 20.
Improvements in PASI 75 in patients with concurrent psoriatic arthritis at baseline were similar to those in the overall plaque psoriasis population. 
Izboljšanje z odzivom PASI 75 pri bolnikih, ki so imeli ob izhodišču sočasno tudi psoriatični artritis, je bilo približno enako pogosto kot v celotni populaciji bolnikov s psoriazo s plaki.
Treatment with secukinumab resulted in significant improvement in measures of disease activity compared to placebo at weeks 16 and 24 (see Table 5). 
Zdravljenje s sekukinumabom je povzročilo statistično značilno večje izboljšanje glede aktivnosti bolezni po 16 in 24 tednih v primerjavi s placebom (glejte preglednico 5).
Secukinumab was administered concomitantly with methotrexate (MTX), sulfasalazine and/or corticosteroids in arthritis studies (including in patients with psoriatic arthritis and ankylosing spondylitis). 
Sekukinumab so uporabljali sočasno z metotreksatom, sulfasalazinom in/ali kortikosteroidi v študijah artritisa (med drugim pri bolnikih s psoriatičnim artritisom in ankilozirajočim spondilitisom).
• Never try to reuse your pen. 
• Že uporabljenega injekcijskega peresnika nikoli ne poskušajte ponovno uporabiti.
Following a single subcutaneous dose of 300 mg as a liquid formulation in healthy volunteers, secukinumab reached peak serum concentrations of 43.2±10.4 μg/ml between 2 and 14 days post dose. 
Po enkratnem subkutanem odmerku 300 mg v tekoči obliki je sekukinumab pri zdravih prostovoljcih dosegel najvišjo koncentracijo v plazmi 43,2±10,4 μg/ml v času med 2. in 14. dnem po odmerjanju.
These instructions are to help you to inject correctly using the Cosentyx SensoReady pen. 
Ta navodila vam bodo pomagala, da boste pri injiciranju zdravila Cosentyx pravilno uporabljali injekcijski peresnik SensoReady.
Similar responses were seen in PsA study 1 and efficacy was maintained up to week 52. 
Podobne odzive so opažali v PsA študiji 1, učinkovitost zdravljenja pa se je ohranila do konca 52. tedna.
The mean volume of distribution during the terminal phase (Vz) following single intravenous administration ranged from 7.10 to 8.60 litres in plaque psoriasis patients, suggesting that secukinumab undergoes limited distribution to peripheral compartments. 
Po odmerjanju enkratnega intravenskega odmerka je pri bolnikih s psoriazo s plaki povprečni volumen porazdelitve v terminalni fazi (Vz) znašal od 7,10 do 8,60 litra, kar kaže, da je porazdelitev sekukinumaba v prostor perifernih predelkov majhna.
Inject the Cosentyx solution subcutaneously into the front of thighs, lower abdomen (but not the area 5 centimetres around the navel) or outer upper arms. 
Subkutano injicirajte raztopino zdravila na sprednjem delu stegen, na spodnjem delu trebuha (vendar ne v predelu, oddaljenem 5 centimetrov ali manj od popka) ali na zunanji strani nadlakti.
A placebo-controlled study evaluated 102 patients with moderate to severe scalp psoriasis, defined as having a Psoriasis Scalp Severity Index (PSSI) score of ≥12, an IGA mod 2011 scalp only score of 3 or greater and at least 30% of the scalp surface area affected. 
V s placebom kontrolirani študiji so ocenjevali bolnike z zmerno do hudo psoriazo lasišča (102 bolnika), ki so imeli po opredelitvi indeks izraženosti psoriaze lasišča (PSSI - Psoriasis Scalp Severity Index) ≥12, oceno izraženosti psoriaze lasišča po modificirani oceni raziskovalca (IGA mod 2011) 3 ali več in prizadetih najmanj 30 % površine lasišča.
In psoriasis, psoriatic arthritis and ankylosing spondylitis clinical studies, less than 1% of patients treated with secukinumab developed antibodies to secukinumab up to 52 weeks of treatment. 
V kliničnih študijah psoriaze, psoriatičnega artritisa in ankilozirajočega spondilitisa je pri manj kot 1% bolnikov, ki so prejemali sekukinumab, prišlo do razvoja protiteles proti sekukinumabu v obdobju do 52 tednov zdravljenja.
The condition is an inflammatory disease primarily affecting the spine which causes inflammation of the spinal joints. 
Gre za vnetno bolezen, ki prizadeene zlasti hrbtenico in povzroča vnetje sklepov med vretenci.
Cosentyx is for long-term treatment. 
Zdravljenje z zdravilom Cosentyx je dolgotrajno.
The single-use vial contains 150 mg secukinumab for reconstitution with sterile water for injections. 
Viala za enkratno uporabo vsebuje 150 mg sekukinumaba, ki ga je treba rekonstituirati s sterilno vodo za injekcije.
Doses up to 30 mg/kg (approximately 2000 to 3000 mg) have been administered intravenously in clinical studies without dose-limiting toxicity. 
V kliničnih študijah so bolnikom intravensko dajali odmerke do 30 mg/kg (približno 2.000 do 3.000 mg) in pri tem ni prišlo do toksičnega delovanja, zaradi katerega bi morali zmanjšati odmerjanje.
Cosentyx is used in adults with active ankylosing spondylitis. 
Zdravilo Cosentyx uporabljamo pri odraslih z aktivnim ankilozirajočim spondilitisom.
• The recommended dose is 150 mg by subcutaneous injection. 
• Priporočeni odmerek je 150 mg s subkutano injekcijo.
All patients received secukinumab 150 mg or 300 mg doses at weeks 0, 1, 2, 3, 4, 8 and 12 and then were randomised to receive either a maintenance regimen of the same dose every month starting at week 12 or a “retreatment as needed” regimen of the same dose. 
Vsi bolniki so prejemali sekukinumab v odmerku 150 mg oziroma 300 mg v tednih 0, 1, 2, 3, 4, 8 in 12, nato pa so jih randomizirali tako, da so zdravilo prejemali bodisi po vzdrževalnem režimu v enakem odmerku enkrat na mesec z začetkom v 12. tednu ali pa po režimu "ponovitve zdravljenja po potrebi" z enakimi odmerki.
Most of the following side effects are mild to moderate. 
Naslednji neželeni učinki so večinoma blago do zmerno izraženi.
The solution should be administered within one hour after removal from 2°C to 8°C storage. 
Raztopino je treba aplicirati v roku 1 ure po premestitvi iz okolja s temperaturo med 2 °C in 8 °C.
9/l (CTCAE grade 3) was reported in 18 out of 3,430 (0.5%) patients on secukinumab, with no dose dependence and no temporal relationship to infections in 15 out of 18 cases. 
9/l (stopnje 3 po Skupnih terminoloških kriterijih za neželene dogodke, CTCAE - Common Terminology Criteria for Adverse Events) so poročali pri 18 od 3.430 (0,5 %) bolnikov, ki so prejemali sekukinumab, pri tem pa pri 15 od 18 primerov reakcija ni bila niti odvisna od odmerka niti časovno povezana z okužbo.
Take the box containing the syringe out of the refrigerator and leave it unopened for about 15-30 minutes so that it reaches room temperature. 
Škatlo z injekcijsko brizgo vzemite iz hladilnika in jo pustite zaprto približno 15-30 minut, da doseže sobno temperaturo.
To prepare Cosentyx 150 mg powder for solution for injection, please adhere to the following instructions: 
Pri pripravljanju zdravila Cosentyx 150 mg prašek za raztopino za injiciranje upoštevajte naslednja navodila:
Exfoliative dermatitis Placebo-controlled clinical studies (phase III) in plaque psoriasis, PsA and AS patients exposed to 300 mg, 150 mg, 75 mg or placebo up to 12 weeks (psoriasis) or 16 weeks (PsA and AS) treatment duration Cases were reported in patients with psoriasis diagnosis 
Bolezni kože in podkožja občasni urtikarija redki eksfoliativni dermatitis s placebom kontrolirane klinične študije (faze III) pri bolnikih s psoriazo s plaki, psoriatičnim artritisom oziroma ankilozirajočim spondilitisom, ki so prejemali odmerek 300 mg, 150 mg, 75 mg ali placebo v okviru zdravljenja, ki je trajalo do 12 tednov (pri psoriazi), ali 16 tednov (pri psoriatičnem artritisu oziroma ankilozirajočem spondilitisu) O primerih so poročali pri bolnikih z diagnozo psoriaze
If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of active psoriatic arthritis, improve physical function and slow down the damage to the cartilage and bone of the joints involved in the disease. 
Če se na zdravljenje s temi zdravili ne bi dobro odzvali, boste dobili zdravilo Cosentyx za zmanjševanje znakov in simptomov aktivnega psoriatičnega artritisa, za izboljšanje telesne zmogljivosti in za zaviranje napredovanja okvar na hrustancu in kostnini v sklepih, ki so prizadeti zaradi bolezni.
Week 24 data are presented in Table 6. 
V preglednici 6 so predstavljeni rezultati po 24 tednih zdravljenja.
Population pharmacokinetic analysis suggests that steady-state is reached after 20 weeks with monthly dosing regimens. 
Rezultati analize populacijske farmakokinetike kažejo, da se stanje dinamičnega ravnovesja pri režimu odmerjanja enkrat na mesec vzpostavi po 20 tednih.
In the placebo-controlled period of clinical studies in plaque psoriasis (a total of 1,382 patients treated with secukinumab and 694 patients treated with placebo for up to 12 weeks), infections were reported in 28.7% of patients treated with secukinumab compared with 18.9% of patients treated with placebo. 
V s placebom kontroliranih obdobjih kliničnih študij psoriaze s plaki (s skupno 1.382 bolniki, ki so do 12 tednov prejemali sekukinumab, in 694 bolniki, ki so prejemali placebo) so o okužbah poročali pri 28,7 % bolnikov, ki so prejemali sekukinumab, v primerjavi z 18,9 % bolnikov, ki so prejemali placebo.
Secukinumab-treated patients reported significant improvements in health-related quality of life as measured by the Short Form-36 Health Survey Physical Component Summary (SF-36 PCS) score (p<0.001). 
Bolniki, ki so prejemali sekukinumab, so navajali statistično značilno povečanje ocene z zdravjem povezane kakovosti življenja po vprašalniku SF-36 PCS (SF-36 PCS - Short Form-36 Health Survey Physical Component Summary) (p<0,001).
Cosentyx is to be administered by subcutaneous injection. 
Zdravilo Cosentyx je treba odmerjati s subkutano injekcijo.
Driving and using machines Cosentyx is unlikely to influence your ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo Cosentyx po vsej verjetnosti ne bo vplivalo na vašo sposobnost vožnje in upravljanja s stroji.
ASDAS-CRP major improvement * p<0.05, ** p<0.01, *** p<0.001; versus placebo All p-values adjusted for multiplicity of testing based on pre-defined hierarchy, except BASDAI 50 and ASDAS-CRP 
* p<0,05, ** p<0,01, *** p<0,001; v primerjavi s placebom Vse vrednosti p so prilagojene na večkratnost testiranja po vnaprej opredeljenem hierarhičnem redu, razen vrednosti p za BASDAI 50 in ASDAS-CRP.
The single and multiple dose pharmacokinetics of secukinumab in plaque psoriasis patients were determined in several studies with intravenous doses ranging from 1x 0.3 mg/kg to 3x 10 mg/kg and with subcutaneous doses ranging from 1x 25 mg to multiple doses of 300 mg. 
Farmakokinetiko sekukinumaba po odmerjanju enkratnega odmerka oziroma večkratnih odmerkov so pri bolnikih s psoriazo s plaki določali v več študijah z intravenskim odmerjanjem od 1x 0,3 mg/kg do 3x 10 mg/kg in v študijah s subkutanim odmerjanjem od 1x 25 mg do več odmerkov po 300 mg.
The condition is an inflammatory disease of the joints, often accompanied by psoriasis. 
Gre za bolezen z vnetjem sklepov, ki ga pogosto spremlja še psoriaza (luskavica).
In PsA study 3, inhibition of progression of structural damage was assessed radiographically and expressed by the modified Total Sharp Score (mTSS) and its components, the Erosion Score (ES) and the Joint Space Narrowing Score (JSN). 
V PsA študiji 3 so zaviranje napredovanja strukturnih okvar ocenjevali radiografsko in izrazili kot spremembo modificirane skupne Sharpove ocene (mTSS-modified total Sharp Score) in njenih komponent, ocene erozije sklepov in ocene zožitve sklepne špranje.
The ASAS 20 and ASAS 40 responses were maintained up to week 156 (69.5% and 47.6% for 150 mg versus 74.8% and 55.6% for 300 mg). 
Odzivi ASAS 20 in ASAS 40 so se ohranili do 156. tedna (69,5 % in 47,6 % v skupini z odmerkom 150 mg v primerjavi s 74,8 % in 55,6 % v skupini z odmerkom 300 mg).
The 300 mg dose provided improved skin clearance particularly for “clear” or “almost clear” skin across the efficacy endpoints of PASI 90, PASI 100, and IGA mod 2011 0 or 1 response across all studies with peak effects seen at week 16, therefore this dose is recommended. 
Odmerek 300 mg je v vseh študijah omogočal zmanjšanje prizadetosti kože zlasti v smislu ocen "brez znakov" ali "skoraj brez znakov" v okviru ciljev študije doseganja odziva PASI 90 oziroma PASI 100 ter odzivov IGA mod 2011 "0" oziroma "1", pri čemer so največji učinek opažali po 16 tednih zdravljenja, zato navedeni odmerek velja kot priporočeni odmerek.
In two additional placebo-controlled studies, improvement was seen in both nail psoriasis (TRANSFIGURE, 198 patients) and palmoplantar plaque psoriasis (GESTURE, 205 patients). 
Specifična mesta prizadetosti/oblike psoriaze s plaki V dveh dodatnih s placebom kontroliranih študijah so opažali izboljšanje tako pri psoriazi s prizadetostjo nohtov (študija TRANSFIGURE, 198 bolnikov) kot pri palmoplantarni obliki psoriaze s plaki (študija GESTURE, 205 bolnikov).
• athlete's foot (tinea pedis) 
• glivična okužba stopal (dermatofitija stopal, tinea pedis),
There were also statistically significant improvements demonstrated in exploratory endpoints assessed by the Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) scores for 150 mg and 300 mg compared to placebo (7.97, 5.97 versus 1.63, respectively) and these improvements were maintained up to week 104 in PsA study 2. 
Dokazali so tudi statistično značilno izboljšanje pri raziskovalnih ciljih študije, ki so jih ocenjevali s pomočjo vprašalnika FACIT-F (FACIT-FFunctional Assessment of Chronic Illness Therapy - Fatigue) pri odmerjanju 150 mg in 300 mg zdravila v primerjavi s placebom (7,97 oziroma 5,97 v primerjavi z 1,63) in to izboljšanje se je v PsA študiji 2 ohranilo do konca 104. tedna.
The safety and efficacy of secukinumab were assessed in four randomised, double-blind, placebo-controlled phase III studies in patients with moderate to severe plaque psoriasis who were candidates for phototherapy or systemic therapy [ERASURE, FIXTURE, FEATURE, JUNCTURE]. 
Varnost in učinkovitost sekukinumaba so ocenjevali v štirih randomiziranih, dvojno slepih, s placebom kontroliranih študijah faze III pri bolnikih, ki so imeli zmerno do hudo psoriazo s plaki in so bili primerni za zdravljenje s fototerapijo ali sistemsko zdravljenje [študije ERASURE, FIXTURE, FEATURE in JUNCTURE].
Mean systemic clearance (CL) following a single intravenous administration to patients with plaque psoriasis ranged from 0.13 to 0.36 l/day. 
Po odmerjanju enkratnega intravenskega odmerka bolnikom s psoriazo s plaki je povprečen sistemski očistek (CL) znašal od 0,13 do 0,36 l/dan.
All p-values are adjusted for multiplicity of testing based on pre-defined hierarchy at week 16 for PsA study 3, except for ACR70 which was an exploratory endpoint and all endpoints at week 24. 
V PsA študiji 3 so za teden 16 vse vrednosti p prilagojene na večkratnost testiranja po vnaprej opredeljenem hierarhičnem redu, razen vrednosti p za odziv ACR 70, ki je bil raziskovalni cilji študije, in za vse cilje študije za teden 24.
For all studies, the primary endpoint was American College of Rheumatology (ACR) 20 response. 
V vseh študijah je bil primarni cilj študije odziv ACR 20 (20-odstotno izboljšanje po merilih Ameriške akademije za revmatologijo, ACR - American College of Rheumatology).
Renal impairment / hepatic impairment Cosentyx has not been studied in these patient populations. 
Zdravila Cosentyx pri teh dveh skupinah bolnikov niso proučevali.
Remove the syringe from the outer box and take it out of the blister. 
Injekcijsko brizgo vzemite iz zunanje škatle in iz pretisnega omota.
Based on population pharmacokinetic analysis, following a single subcutaneous dose of either 150 mg or 300 mg in plaque psoriasis patients, secukinumab reached peak serum concentrations of 13.7±4.8 µg/ml or 27.3±9.5 µg/ml, respectively, between 5 and 6 days post dose. 
Po rezultatih analize populacijske farmakokinetike je po enkratnem subkutanem odmerku bodisi 150 mg ali 300 mg sekukinumab pri bolnikih s psoriazo s plaki dosegel najvišjo koncentracijo v plazmi 13,7±4,8 µg/ml oziroma 27,3±9,5 µg/ml v času med 5. in 6. dnem po odmerjanju.
In a population pharmacokinetic analysis, the mean systemic clearance (CL) was 0.19 l/day in plaque psoriasis patients. 
Po rezultatih analize populacijske farmakokinetike je pri bolnikih s psoriazo s plaki povprečen sistemski očistek (CL) znašal 0,19 l/dan.
Solution for injection in pre-filled pen (SensoReady pen) 
raztopina za injiciranje v napolnjenem injekcijskem peresniku (injekcijskem peresniku SensoReady)
The frequency of IL-17-producing cells was also significantly higher in the subchondral bone marrow of facet joints from patients with ankylosing spondylitis. 
Koncentracija celic, v katerih nastaja IL-17A, je bila prav tako bistveno večja v subhondralnem kostnem mozgu pod fasetnimi sklepi pri bolnikih z ankilozirajočim spondilitisom.
PsA study 1 
PsA študija 1
Included in the carton: 
V škatli najdete:
For psoriatic arthritis patients who also have moderate to severe plaque psoriasis or patients who did not respond well to medicines called tumour necrosis factor (TNF) blockers: 
Za bolnike s psoriatičnim artritisom, ki imajo poleg tega zmerno do hudo psoriazo s plaki, in za bolnike z nezadostnim odzivom na predhodno zdravljenje z zdravili, ki jih imenujemo zaviralci tumorje nekrotizirajočega faktorja:
The primary endpoint was ASAS 20 at week 16. 
Primarni cilj študije je bil dosežen odziv ASAS 20 po 16 tednih.
Do not use this medicine if you notice that the powder has not fully dissolved or if the liquid contains easily visible particles, is cloudy or is distinctly brown. 
Zdravila ne uporabljajte, če opazite, da se prašek ni raztopil v celoti ali če tekočina vsebuje jasno vidne delce, je motna ali izrazito rjave barve.
Weeks of treatment n = number of patients evaluable secukinumab 150 mg (n=243) 
odstotek spremembe vrednosti indeksa PASI od izhodišča tedni zdravljenja n = število bolnikov, primernih za ocenjevanje number of patients evaluable sekukinumab 150 mg (n=243)
PsA study 3 (FUTURE 5) evaluated 996 patients, of whom 50.1% had concomitant MTX. 
V PsA študiji 3 (študiji FUTURE 5) so ocenjevali 996 bolnikov, od katerih jih je 50,1 % sočasno prejemalo še metotreksat.
Cosentyx is given via injection under your skin (known as a subcutaneous injection). 
Zdravilo Cosentyx je treba dajati z injekcijo pod kožo (kar imenujemo subkutano injiciranje).
Using Cosentyx in psoriatic arthritis will benefit you by reducing the signs and symptoms of the disease, slowing down the damage to the cartilage and bone of the joints and improving your ability to do normal daily activities. 
Pri psoriatičnem artritisu vam bo uporaba zdravila Cosentyx koristila, saj bo zmanjševala znake in simptome bolezni, zavirala napredovanje okvar hrustanca in kostnine v sklepih in izboljševala vašo zmogljivost za opravljanje običajnih vsakodnevnih dejavnosti.
Week 52 Placebo 150 mg 300 mg 150 mg 300 mg 150 mg 300 mg 
po 12 tednih po 16 tednih po 52 tednih placebo 150 mg 300 mg 150 mg 300 mg 150 mg 300 mg
Secukinumab 300 mg met the primary and secondary endpoints by showing superiority to ustekinumab based on PASI 90 response at week 16 (primary endpoint), speed of onset of PASI 75 response at week 4, and long-term PASI 90 response at week 52. 
Za odmerek 300 mg sekukinumaba so tako pri primarnem kot pri sekundarnih ciljih študije lahko dokazali boljše rezultate (superiornost) v primerjavi z ustekinumabom pri doseganju odziva PASI 90 v 16. tednu (primarni cilj študije), hitrosti nastopa odziva PASI 75 v 4. tednu in dolgoročnem odzivu PASI 90 v 52. tednu.
Before reconstitution: Store the vial in the refrigerator between 2°C and 8°C. 
Pred rekonstitucijo: Vialo shranjujte v hladilniku pri temperaturi od 2 °C do 8 °C.
Cosentyx 150 mg powder for solution for injection must be prepared by a healthcare professional. 
Zdravilo Cosentyx 150 mg prašek za raztopino za injiciranje mora pripraviti zdravstveni delavec.
In PsA study 1, inhibition of structural damage was maintained with secukinumab treatment up to week 52. 
V PsA študiji 1 se je zaviranje napredovanja strukturnih okvar pri uporabi sekukinumaba ohranilo do konca 52. tedna.
Live vaccines should not be given concurrently with secukinumab (see also section 4.4). 
Bolniki v času zdravljenja s sekukinumabom ne smejo prejeti živih cepiv (glejte tudi poglavje 4.4).
IGA mod 2011 “clear” or “almost clear” response n (%) * The IGA mod 2011 is a 5-category scale including “0 = clear”, “1 = almost clear”, “2 = mild”, “3 = moderate” or “4 = severe”, indicating the physician's overall assessment of the psoriasis severity focusing on induration, erythema and scaling. 
* IGA mod 2011 je lestvica s 5 kategorijami možne ocene, in sicer "0 = brez znakov", "1 = skoraj brez znakov", "2 = blaga", "3 = zmerna" in "4 = huda", ki se nanašajo na zdravnikovo oceno celotne izraženosti psoriaze s poudarkom na oceni zadebelitve, rdečine in luščenja kože.
Do not use this medicine if either the seal on the outer box or the seal of the blister is broken, as it may not be safe for you to use. 
Če zunanja škatla ali pretisni omot nista originalno zaprta, ne uporabljajte tega zdravila, saj morda ni varno za uporabo.
Compared with exposure after a single dose, the population pharmacokinetic analysis showed that patients exhibited a 2-fold increase in peak serum concentrations and area under the curve (AUC) following repeated monthly dosing during maintenance. 
Pri rednem odmerjanju enkrat na mesec v času vzdrževalnega zdravljenja so po rezultatih analize populacijske farmakokinetike v primerjavi z izpostavljenostjo zdravilu po enkratnem odmerku pri bolnikih izmerili 2-krat višje vrednosti najvišje koncentracije v serumu in površine pod krivuljo časovnega poteka koncentracije (AUC).
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. 
Zdravilo Cosentyx je indicirano za zdravljenje zmerne do hude psoriaze s plaki pri odraslih, ki so primerni za sistemsko zdravljenje.
The onset of action of secukinumab occurred as early as week 2. 
Sekukinumab je začel delovati že v 2. tednu zdravljenja.
If you forget to use Cosentyx If you have missed a Cosentyx injection, talk to your doctor. 
Če ste izpustili injiciranje zdravila Cosentyx, se posvetujte z zdravnikom.
Using Cosentyx in plaque psoriasis will benefit you by leading to improvements of skin clearance and reducing your symptoms such as scaling, itching and pain. 
Pri psoriazi s plaki vam bo uporaba zdravila Cosentyx koristila, saj bo odpravljala kožne spremembe in zmanjševala simptome, kot so luščenje, srbenje in bolečine.
In clinical studies, rare cases of anaphylactic reactions have been observed in patients receiving secukinumab. 
V kliničnih študijah so pri bolnikih, ki so prejemali sekukinumab, v redkih primerih opažali anafilaktične reakcije.
If you do not respond well enough to these medicines, you will be given Cosentyx to reduce the signs and symptoms of the disease, reduce inflammation and improve your physical function. 
Če se na zdravljenje s temi zdravili ne bi dobro odzvali, boste dobili zdravilo Cosentyx za zmanjševanje znakov in simptomov bolezni, za zmanjševanje vnetja in izboljšanje telesne zmogljivosti.
• if the liquid contains easily visible particles, is cloudy or is distinctly brown. 
• če raztopina vsebuje jasno vidne delce, je motna ali izrazito rjave barve.
Using Cosentyx in ankylosing spondylitis will benefit you by reducing the signs and symptoms of your disease and improving your physical function. 
Pri ankilozirajočem spondilitisu vam bo uporaba zdravila Cosentyx koristila, saj bo zmanjševala znake in simptome bolezni ter izboljševala vašo telesno zmogljivost.
Figure 2 ACR20 response in PsA study 2 over time up to week 52 
Slika 2 Časovni potek doseganja odziva ACR 20 v PsA študiji 2 do 52. tedna
The removable needle cap of the Cosentyx pre-filled syringe contains a derivative of natural rubber latex. 
Snemljiv pokrovček igle napolnjene injekcijske brizge z zdravilom Cosentyx vsebuje derivat naravnega lateksa.